Vyondys 53

Chemical Namegolodirsen
Dosage FormInjectable (intravenous; 50 mg/mL)
Drug ClassOligonucleotides
CompanySarepta Therapeutics Inc.
Approval Year2019


  • Vyondys 53 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.
Last updated on 6/11/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Vyondys 53 (golodirsen) Prescribing Information2019Sarepta Therapeutics